Seeking Alpha

Todd Walker's  Instablog

Todd Walker
Send Message
Todd Walker is the Executive Director and Chief Strategist at HedgeTracker, where he is responsible for overseeing research, analytics and business development. He has particular expertise in investments that are popular among elite hedge fund managers, shareholder activists and... More
My company:
HedgeTracker.com
My blog:
View Todd Walker's Instablogs on:
  • Top Performing Healthcare & Biotech Hedge Funds Share Convictions For Top Stock Opportunities

    A recent analysis of the top long-term performing Healthcare, Pharma & Biotech Hedge Funds has revealed that the top funds share a number of the same top investment ideas. The top four hedge funds include Viking Global Investors, Glenview Capital Management, Visium Asset Management LLC and Ratan Capital Management. To make the list, the hedge funds had to be ranked on:

    1. Hedge Tracker's Top 50 Healthcare, Pharma & Biotech Hedge Fund List, which only includes funds that have more than 35% of their U.S. equity assets invested in Healthcare, Pharma and Biotech companies as of 6/30/2014.
    2. Barron's Best 100 Hedge Funds List, which required a 3 year Compound Annual Return of at least 12.25% through the end of 2013.

    At the end of Q2, all of the top Healthcare hedge funds, with the exception of Ratan Capital, held an equity stake in Thermo Fisher Scientific (NYSE:TMO). Combined, the three hedge funds hold approximately $2.3 billion in the analytical instruments and laboratory equipment company. Larry Robbins' Glenview Capital has the largest stake, having reported holdings of 10.9 million shares in TMO. The stock is up 11.4% year-to-date, and ended the week at $123.24. Equity analysts have TMO's one year target estimate at $143.07, according to Yahoo, highlighting its upside potential.

    Valeant Pharmaceuticals (NYSE:VRX) and Allergan Inc (NYSE:AGN) have also attracted the attention of the top Healthcare hedge funds, with Viking Global, Visium and Ratan Capital holding stakes. Earlier this year, VRX implemented a "poison pill" to deter a takeover attempt by AGN, which was being embarked on in partnership with Bill Ackman's Pershing Square Capital.

    Combined, the top three hedge funds hold a total of $1.6B in VRX, with Viking' stake accounting for $1.49B of the total. Their combined holdings in AGN are valued at $631M, with Visium's stake accounting for $409M of the total. AGN's stock has had a stellar year so far, having seen its stock price jump 51.4% YTD, ending the week at $168.21. Equity analysts have the stock's one year target estimate at $200.60, according to Yahoo, making me bullish on AGN's prospects.

    Endo International (NASDAQ:ENDP) is another favorite of the top funds, with Glenview, Visium and Ratan all holding stakes. Combined, the three hedge funds hold approximately $636M in the specialty pharmaceutical company. So far, ENDP's stock is only up 0.4% year-to-date, ending the week at $67.70. Equity analysts have ENDP's one year target estimate at $75.55, according to Yahoo, highlighting a potential buying opportunity.

    Glenview Capital, Viking Global, and Visium are also holders of Wellpoint Inc (NYSE:WLP), holding stakes of $489M, $103M and $12M, respectively. WLP's stock has had a strong year so far, having seen its stock price jump 32.1% YTD, ending the week at $122.04. Equity analysts have the stock's one year target estimate at $118.87, according to Yahoo. While I don't have WLP as a buy, I would reconsider it if it dips below $110.

    Finally, while Walgreen Co (NYSE:WAG) is not exactly a healthcare company, all four of the top hedge funds have a stake in the large drug retailing chain. Combined, the top funds hold approximately $1.8B in WAG, with Viking Global accounting for $1.5B. WAG's stock is up 9.5% year-to-date, ending the week at $62.88. Equity analysts have the stock's one year target estimate at $71.50, according to Yahoo, highlighting a buying opportunity.

    Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it. The author has no business relationship with any company whose stock is mentioned in this article.

    Sep 23 8:18 AM | Link | Comment!
  • Assets For Top Technology, Media & Telecom Hedge Funds Up $2.4B YTD; Lone Pine Steals Top Spot From Coatue Capital

    The latest Top Technology, Media and Telecom Hedge Fund list has been released, revealing that the top TMT Funds currently manage almost $132 billion in equity assets, up nearly 2% year-to-date. Philippe Laffont's Coatue Capital no longer holds the top spot on the list, a position his hedge fund firm had held since the TMT list was first compiled.

    Steve Mandel's Lone Pine Capital notably shifted more of his portfolio into the TMT stocks over the past quarter, placing Lone Pine in the top spot on The Top 50 TMT Hedge Fund List for the first time. Lone Pine reported $11.7 billion in assets devoted to TMT, or nearly than 53% of its equity assets under management. Lone Pine's TMT assets are aggressively allocated to some of the largest tech companies, including investments of $1.4B in Cognizant Technology (NASDAQ:CTSH), $1.2B in Baidu Inc (NASDAQ:BIDU), and $1.2B in Microsoft (NASDAQ:MSFT).

    Lone Pine's move into the TMT space is especially notably due to the fact that the firm was been named the industry's most profitable hedge fund in both 2013 and 2012, according to a study conducted by LCH Investments NV.

    ValueAct Capital claimed the #2 spot on this quarter's list, having climbed up one spot over the quarter. ValueAct, a San Francisco-based long/short equity investor, reported $6.7 billion in TMT assets, amounting to more than half of its total equity assets. Like last quarter, ValueAct concentrated its TMT portfolio holdings into three stocks, including investments of $2.9B in Microsoft Corp (MSFT), $1.9B in Motorola Inc (NYSE:MSI) and $1.7B in Adobe Systems Inc (NASDAQ:ADBE).

    Philippe Laffont's Coatue Capital, which fell two spots to third, rounds out the top three TMT investors. Laffont is considered a "Tiger Cub", having refined his investment acumen under the tutelage of Julian Robertson, before founding Coatue in 1999. Coatue Capital reported $5.2 billion in TMT assets, or nearly than 93% of the firm's equity assets under management. Coatue's top stock picks include $543M in Netflix (NASDAQ:NFLX), $434 in Baidu Inc (BIDU), $417M in CBS Corp (NYSE:CBS), $380M in Facebook (NASDAQ:FB), $306M in Time Warner (NYSE:TWX), $282M in Micron Technology (NASDAQ:MU) and $274M in Linkedin Corp (NYSE:LNKD).

    Overall, the top hedge funds allocate $85 billion, or 64% of their equity assets to TMT stocks.

    Ranking Methodology: The Top 50 TMT Hedge Fund rankings are compiled on a quarterly basis using hedge fund firms' overall U.S. equity assets under management. The TMT list includes the top hedge funds that have more than 50% of their U.S. equity assets invested in U.S. listed Technology, Media and Telecom companies. To view the Top TMT Hedge Fund list in its entirety, please visit Hedge Tracker's Hedge Fund Portal.

    Jul 01 10:54 AM | Link | Comment!
  • Top Healthcare And Biotech Focused Hedge Funds Surge; Oversee $70 Billion In Equity Assets

    The most recent Top 50 Healthcare, Pharmaceutical and Biotechnology Focused Hedge Fund list has been released, revealing that the top hedge funds now manage $70 billion in U.S. equity assets. Larry Robbins' Glenview Capital Management has retained the top spot, once again, with $13.2 billion in equity assets under management. Glenview Capital's sector favorites include Thermo Fisher Scientific (NYSE:TMO), HCA Holdings Inc (NYSE:HCA) and Health Management Associates (NYSE:HMA). Over the last quarter, Glenview Capital notably increased its bets on Tenet Healthcare (NYSE:THC) and Aetna Inc (NYSE:AET).

    Other top investors that lead the Top Healthcare, Pharma and Biotech Hedge Fund List include #2 OrbiMed Advisors, #3 Baker Bros. Advisors LLC, and #4 Partner Fund Management. The largest investments for OrbiMed Advisors, which is run by industry stalwart Samuel Isaly, include Gilead Sciences Inc (NASDAQ:GILD), Biogen Idec Inc (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). Notably, Isaly's firm entered and bought up large stakes in Relypsa Inc (NASDAQ:RLYP), Perrigo Co (NYSE:PRGO) and Acceleron Pharma (NASDAQ:XLRN) over the quarter, while also increasing its stakes in Abbvie Inc (NYSE:ABBV) and Celgene Corp (NASDAQ:CELG).

    Baker Bros. Advisors' top positions include Pharmacyclics Inc (NASDAQ:PCYC), Seattle Genetics (NASDAQ:SGEN) and Incyte Corp (NASDAQ:INCY), while Partner Fund Management's top industry picks include Gilead Sciences Inc (GILD), Bristol-Myers Squibb (BMY) and Actavis Inc (NYSE:ACT).

    Ranking Methodology: The Top Healthcare, Pharmaceutical and Biotechnology Hedge Fund rankings are compiled on a quarterly basis using hedge fund firms' overall U.S. equity assets under management. The list includes the top hedge funds that have more than 35% of their U.S. equity assets invested in U.S. listed Healthcare, Pharma & Biotech companies. To view the Top Healthcare, Pharma & Biotech Hedge Fund list in its entirety, please visit HedgeTracker's Hedge Fund Portal.

    Apr 21 12:00 AM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.